Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

haleon portugal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração

Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

haleon portugal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

haleon portugal, lda. - dimetindeno - gotas orais, solução - 1 mg/ml - dimetindeno, maleato 1 mg/ml - dimetindene - n/a - duração do tratamento: curta ou média duração

Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

baldacci - portugal, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

baldacci - portugal, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração